Peficitinib
|
|
|
- CAS-Nr.
- 944118-01-8
- Englisch Name:
- Peficitinib
- Synonyma:
- Carotegrast methyl;1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)amino]-, stereoisomer;CS-2584;Peficitinib;JNJ-54781532;JNJ-54781533;Peficitinib ASP015K;ASP015K;JNJ-54781532;Piraxostat Impurity 34;Peficitinb (ASP015K, JNJ-54781532)
- CBNumber:
- CB32730346
- Summenformel:
- C18H22N4O2
- Molgewicht:
- 326.39
- MOL-Datei:
- 944118-01-8.mol
|
Peficitinib Eigenschaften
- storage temp.
- Store at -20°C
- Löslichkeit
- Soluble in DMSO
- Aggregatzustand
- Powder
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Peficitinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Peficitinib can be used in therapeutic use and biological study of codrug and preparation of bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators.
Enzyminhibitor
This orally bioavailable JAK inhibitor and anti-rheumatoid arthritis drug (FW = 326.39 g/mol; CAS 944118-01-8; Solubility: 200 mM in DMSO), also named ASP015K, JNJ-54781532, and trans-4-[[5-hydroxy-2- adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, targets Janus Kinase JAK1, JAK2, JAK3 and the nonreceptor tyrosine kinase Tyk2 enzyme with IC50 values of 3.9, 5.0, 0.71 and 4.8 nM, respectively. Itsselectively suppress JAK3 or JAK1/2, respectively, may explain the weaker effects on red blood cells and platelets reported to be caused by JAK2 inhibition. Moreover, peficitinib improves symptoms in RA animal models after once-daily oral administration and demonstrates dosedependent improvement in psoriatic disease activities in a 6-week phase IIa study. The terminal mean half-life of peficitinib is 7–13 hours in pharmacological studies with healthy subjects
Peficitinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Peficitinib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 87)Lieferanten
- Peficitinib
- 4-[(trans-5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
- Peficitinib (ASP015K, JNJ-54781532)
- JNJ-54781532
- ASP015K;JNJ-54781532
- CS-2584
- Peficitinb (ASP015K, JNJ-54781532)
- 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
- ASP015K;JNJ-54781532;ASP-015K;ASP 015K;JNJ54781532;JNJ 54781532
- 4-(((1R,2s,3S,5r)-5-hydroxyadamantan-2-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
- Peficitinib ASP015K
- JNJ-54781533
- Carotegrast methyl
- 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)amino]-, stereoisomer
- JAK,Janus kinase,lymphocytes,JNJ 54781532,Peficitinib,JNJ54781532,Inhibitor,rheumatoid arthritis,inhibit,IL-2,splenocytes
- Piraxostat Impurity 34
- 944118-01-8
- Inhibitor
- Anti-cancer
